血清固定早期梅毒患者经苄星青霉素再治疗后的血清学应答
基线及6个月时非密螺旋体抗体滴度较高的患者更易在再治疗后出现血清学治愈。
要点
- 34例(48.6%)在再治疗后6个月内快速血浆反应素试验抗体滴度较基线至少下降4倍。
- 基线及6个月时非密螺旋体抗体滴度较高者更易在再治疗后出现血清学治愈。
核心结论
- 作者认为,考虑到随访时血清学应答与血清固定状态的比例接近1:1,对早期梅毒血清固定患者进行再治疗的增量获益为中等程度。
研究设计与样本
- 血清学再治疗成功定义为基线快速血浆反应素试验抗体滴度在6个月内至少下降4倍。
主要发现
- 34例(48.6%)在初始治疗后6个月未达到血清学治愈的患者在12个月时达到血清学治愈。
- 基线及6个月时非密螺旋体抗体滴度较高的患者比滴度较低者更易在再治疗后出现血清学治愈。
关键数值与推荐
- 血清学再治疗成功定义为基线快速血浆反应素试验抗体滴度在6个月内至少下降4倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some syphilitic patients remain in a serologically positive state after the recommended therapy. Although we often retreat patients in clinical practice, the optimal treatment protocol remains uncertain due to the paucity of data regarding serological response to retreatment and long-term outcomes. METHODS: We examined rapid plasma reagin serological test results of 70 serofast early syphilis cases who were retreated with 2.4 million units of benzathine penicillin weekly for 3 weeks. Serological retreatment success was defined as a minimum 4-fold decrease in baseline rapid plasma reagin test antibody titre within 6 months. RESULTS: Thirty-four (48.6%) of the patients who failed to achieve serological cure at 6 months after initial therapy achieved serological cure at 12 months. Patients who had higher non-treponemal titres at baseline and at 6 months were more likely to exhibit serological cure after retreatment than those with lower titres. CONCLUSIONS: Our results suggest that the incremental benefit of retreating serofast patients with early syphilis is moderate, considering the almost 1:1 ratio of serological response to serofast state at follow-up.
引用
- Wang ZS, Liu XK, Li J, et al. Serological response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. J Antimicrob Chemother. 2018. PMID: 29394361. doi:10.1093/jac/dky006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。